In preclinical studies at Sunshine Lake Pharma Co. Ltd., researchers investigated the antiviral and immune-modulatory potential of HEC-191834, a novel and highly selective human Toll-like receptor 8 (TLR8) agonist, in chronic hepatitis B virus (HBV) models, as well as its activity when combined with siRNA.
Innovent Biologics (Suzhou) Co. Ltd. has described antibody-stimulating antibody conjugates (ISACs) comprising antibody targeting folate receptor α (FOLR1; FR-α) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently bound to toll-like receptor 7 (TLR7) and/or toll-like receptor 8 (TLR8) agonist through a linker reported to be useful for the treatment of cancer.
Miracure Biotechnology Ltd. has divulged Toll-like receptor 7 (TLR7) and/or TLR8 agonists reported to be useful for the treatment of cancer, infections, respiratory disorders and immunological disorders.
Beijing Synthetic Vaccine Biosciences Co. Ltd. has synthesized Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of autoimmune disease, cancer, inflammatory disorders and viral infection.
Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged compounds acting as Toll-like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer.
Shanghai De Novo Pharmatech Co. Ltd. has described antibody-immunostimulatory conjugates consisting of an antibody covalently bound to Toll-like receptor 8 (TLR8) agonists through a linker reported to be useful for the treatment of cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described Toll-like receptor 7 (TLR7) and/or TLR8 agonists and their immunostimulatory antibody conjugates (ISACs) consisting of antibodies covalently linked to TLR7 and/or TLR8 agonists through cleavable or uncleavable linkers.
Legochem Biosciences Inc. has synthesized Toll-like receptor 7 (TLR7) and/or TLR8 agonists reported to be useful for the treatment of cancer, HIV infection, and hepatitis B virus infection.
